Unicycive Therapeutics Announces Resubmission of New Drug Application for Oxylanthanum Carbonate
Unicycive Therapeutics (Nasdaq: UNCY) resubmitted its NDA for oxylanthanum carbonate, an oral phosphate binder for CKD patients on dialysis. The resubmission includes new CMC data from a different vendor. The company expects FDA acceptance within 30 days and a PDUFA date 6 months from resubmission. Unicycive has $61.4M in cash, supporting operations into 2H 2027.
How this was made
The 30-second read
Why it matters
The NDA resubmission signals progress toward potential market entry, but the outcome hinges on FDA review and vendor inspections.
Market read
A positive FDA decision could drive a short‑term rally in UNCY; a negative outcome may trigger sell‑off.
What to watch
Cash runway to 2H 2027 reduces immediate financing risk, but the company remains dependent on a single product.
Background
Unicycive Therapeutics (NASDAQ: UNCY) is a clinical‑stage biotech focused on kidney disease treatments. Its lead candidate OLC is an oral phosphate binder.
Ticker impact
Unicycive Therapeutics announced the resubmission of its NDA for oxylanthanum carbonate, expecting FDA acceptance within 30 days and a new PDUFA date six months out.
potential upside if FDA accepts the NDA; possible pressure if inspection issues arise
Regulatory acceptance is a binary catalyst; the new vendor's clean inspection improves odds, but the original vendor's pending inspection creates uncertainty.
Market effects
May boost sentiment for kidney‑disease biotech peers if FDA moves favorably.
Limited to US biotech sector; no broader regional effect.
Low global impact beyond niche renal‑therapy market.
Counterpoint
Investors may short on the risk that the original vendor's inspection could delay approval.
Key entities
- companyUnicycive Therapeutics
Biotech developer of oxylanthanum carbonate.
- regulatorFDA
U.S. agency reviewing the NDA.
